CORONAVIRUS INFO PROVIDED BY DR. JIM HARRIS – 08/17/2021
From MNM and Judge Sims: Harrison County Cases have doubled: 52 new cases daily.
From USA Today:
”…Biden administration officials are expected to recommend COVID-19 booster shots for all Americans, regardless of age, eight months after they received the second shot, a source confirmed to USA TODAY late Monday. The news, which will be announced as soon as this week, comes as the delta variant rages across the country. It also comes amid anxieties about the Pfizer vaccine’s waning immunity and the Food and Drug Administration’s approval of booster vaccines for immunocompromised people. Data published by Israel’s Ministry of Health shows protection from the Pfizer/BioNTech vaccine dropped off after six months. “It gets down to the 40 to 50% effectiveness range, whereas it used to be 95%,” said Dr. Eric Topol, an expert on the use of data in medical research. Booster shots will begin as early as mid-September once the FDA formally approves vaccines.”
FROM HOPKINS CITATIONS:
1. Durability of mRNA-1273 Vaccine–induced Antibodies Against SARS-CoV-2 Variants (Science) Here, we assess the impact of SARS-CoV-2 variants B.1.1.7 (Alpha), B.1.351 (Beta), P.1 (Gamma), B.1.429 (Epsilon), B.1.526 (Iota), and B.1.617.2 (Delta) on binding, neutralizing, and ACE2-competing antibodies elicited by the vaccine mRNA-1273 over seven months. Cross-reactive neutralizing responses were rare after a single dose. At the peak of response to the second vaccine dose, all individuals had responses to all variants. Binding and functional antibodies against variants persisted in most subjects, albeit at low levels, for 6-months after the primary series of the mRNA-1273 vaccine. Across all assays, B.1.351 [S. AFRICA] had the lowest antibody recognition. These data complement ongoing studies to inform the potential need for additional boost vaccinations.
(J. Harris: A mostly immunized, isolated population has a Delta outbreak, but only 2% of the infected are in the hospital, and nobody who is immunized dies. THIS PROVES THE IMMUNIZATION PROTECTS.)
3. Change in Saliva RT-PCR Sensitivity Over the Course of SARS-CoV-2 Infection (JAMA) We tested 889 paired nasopharyngeal swab-saliva samples from 404 participants, of which SARS-CoV-2 was detected in 524 nasopharyngeal (58.9%) and 318 saliva (35.7%) specimens. SARS-CoV-2 was detected in both specimens in 258 pairs (29.0%). Saliva was sensitive for detecting SARS-CoV-2 in symptomatic individuals during initial weeks of infection, but sensitivity in asymptomatic SARS-CoV-2 carriers was less than 60% at all time points. As COVID-19 testing strategies in workplaces, schools, and other shared spaces are optimized, low saliva sensitivity in asymptomatic infections must be considered.5 This study suggests saliva-based RT-PCR should not be used for asymptomatic COVID-19 screening.